Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Summary 
Mr. Daniel E. Geffken is a CFO, Principal Financial & Accounting Officer at OPY Acquisition Corp. I, a Chief Financial Officer at Phoenix Biotech Acquisition Corp., a Chief Financial & Accounting Officer at Eloxx Pharmaceuticals, Inc., a Chief Financial Officer at CalciMedica, Inc., a Chief Financial Officer at DermBiont, Inc., a Chief Financial Officer at Palvella Therapeutics, Inc., a Chief Financial Officer at Privo Technologies, Inc., a Chief Financial Officer at Zikani Therapeutics, Inc., an Independent Director at Windtree Therapeutics, Inc., a Chief Financial Officer at Apic Bio, Inc., a Chief Financial Officer at Vigeo Therapeutics, Inc., a Chief Financial Officer at ProMIS Neurosciences, Inc., a Chief Financial Officer at Antolrx, Inc., a Chief Financial Officer & Director at Elicio Therapeutics, Inc., a Co-Managing Director at Danforth Advisors LLC, a Chief Financial Officer at Artax Biopharma, Inc., a Chief Financial Officer at Clear Creek Bio, Inc., a Chief Financial Officer at GenePeeks, Inc., a Chief Financial Officer at Matrivax Research & Development Corp., a Chief Financial Officer at Myeloid Therapeutics, Inc., a Chief Financial Officer at Nemucore Medical Innovations, Inc., a Chief Financial Officer at Prilenia Therapeutics Development Ltd., a Chief Financial Officer at United Neuroscience Ltd., a Chief Financial Officer at Vaxxinity, Inc. and a Chief Financial Officer at Windgap Medical, Inc.

He is on the Board of Directors at Windtree Therapeutics, Inc., Elicio Therapeutics, Inc. and SG DAN Holdings LLC. Mr. Geffken was previously employed as a Chief Financial Officer by Locust Walk Acquisition Corp., a Chief Financial Officer by Cabaletta Bio, Inc., an Independent Director by Arcturus Therapeutics Ltd., a Chief Financial Officer by Stealth BioTherapeutics Corp., a Chief Financial Officer by Apellis Pharmaceuticals, Inc.,


Current positions of Daniel E. Geffken 
NameTitle Since
Phoenix Biotech Acquisition Corp.
(Investment Holding Companies)
Chief Financial Officer 2021
OPY Acquisition Corp. I
(Investment Holding Companies)
Chief Financial Officer & Secretary 2021
ProMIS Neurosciences, Inc.
(Biotechnology & Medical Research)
Chief Financial Officer 2017
Windtree Therapeutics, Inc.
(Biotechnology & Medical Research)
Independent Director 2019
Eloxx Pharmaceuticals, Inc.
(Biotechnology & Medical Research)
Chief Financial & Accounting Officer 2021
Antolrx, Inc. Chief Financial Officer 2016
Matrivax Research & Development Corp. Chief Financial Officer -
Myeloid Therapeutics, Inc. Chief Financial Officer -
Prilenia Therapeutics Development Ltd. Chief Financial Officer -
Privo Technologies, Inc. Chief Financial Officer 2020
Apic Bio, Inc. Chief Financial Officer 2018
Clear Creek Bio, Inc. Chief Financial Officer -
DermBiont, Inc. Chief Financial Officer 2020
Palvella Therapeutics, Inc. Chief Financial Officer 2020
United Neuroscience Ltd. Chief Financial Officer -
Vigeo Therapeutics, Inc. Chief Financial Officer 2017
GenePeeks, Inc. Chief Financial Officer -
Nemucore Medical Innovations, Inc. Chief Financial Officer -
Zikani Therapeutics, Inc. Chief Financial Officer 2019
Windgap Medical, Inc. Chief Financial Officer -
Artax Biopharma, Inc. Chief Financial Officer -
CalciMedica, Inc. Chief Financial Officer 2020
SG DAN Holdings LLC Director -
Elicio Therapeutics, Inc. Chief Financial Officer & Director 2014
Danforth Advisors LLC Co-Managing Director 2011


Holdings of Daniel E. Geffken 
NameEquities%Valuation
Eloxx Pharmaceuticals, Inc. (ELOX)
(Biotechnology & Medical Research)
50,0000.058%15,000 USD
Windtree Therapeutics, Inc. (WINT)
(Biotechnology & Medical Research)
7,0690.024%3,443 USD
ProMIS Neurosciences, Inc. (PMN)
(Biotechnology & Medical Research)
00.0000%0 USD


Daniel E. Geffken: Personal Network 
Most Read News 
06/22ELON MUSK : Musk says Tesla's new car factories 'losing billions of dollars'
RE
06/28WARREN BUFFETT : Buffett's Berkshire buys more Occidental shares, raises stake to about 16.4%
RE
06/29MUKESH AMBANI : Factbox-Ambani children at centre of leadership change at India's Reliance
RE
06/23MARK MILLER : Column-Want to do something about your ailing retirement savings? Don't
RE
06/28RALPH HAMERS : UBS head of strategy to depart bank for entrepreneurship
RE
06/22TREVOR MILTON : Nikola founder Trevor Milton faces new fraud charge
RE
06/22RUPERT MURDOCH : Rupert Murdoch and Jerry Hall are getting a divorce - NYT
RE
06/21ELON MUSK : Musk says there are still a few unresolved matters with Twitter deal
RE
06/23MASAYOSHI SON : Nasdaq listing most likely for Arm - SoftBank's Son
RE
06/30MARK ZUCKERBERG : engineering hiring target for 2022 reduced to around 6,000-7,000 -employee Q&A
RE
More news


© 2022 People and Ownership :   
Daniel E. Geffken : Connections